All research
Survodutide 2026-06-08 EuropePMC

Review clarifies Survodutide's dual-agonist mechanism and promising clinical performance for obesity and liver disease

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Abstract

A plain language review clarifies survodutide's dual-agonist mechanism and promising clinical performance for obesity and liver disease.


Source: europepmc:epmc_PMC13241674 · Ingested 2026-06-08 · Digest: gemini-2.5-flash